Skip to main content
letter
. 2017 Mar 14;18:123. doi: 10.1186/s13063-017-1843-5

Table 5.

Recurrence rate and median recurrence-free survival (RFS) for Keyhole Limpet Hemocyanin (KLH) and mitomycin C (MM) in patients with recurrence and complete treatment course who received additional treatment after transurethral resection of bladder tumor (TURBT) for prior tumor (KLH second-line treatment)

Recurrence rate (%) Median (weeks) 95% confidence interval
Lower bound Upper bound
KLH 48 235 35 435
Mitomycin C 52 98 75 121
Overall 50 210 69 351